BSA
AZN icon

Braun Stacey Associates’s AstraZeneca AZN Stock Holding History

Braun Stacey Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,163
Closed -$1.59M – 117
2024
Q2 		$1.59M Sell
10,163
-23,751
-70% -$3.57M 0.06% 93
2024
Q1 		$4.59M Sell
33,914
-21,838
-39% -$2.89M 0.18% 89
2023
Q4 		$7.51M Sell
55,752
-14,295
-20% -$1.86M 0.34% 88
2023
Q3 		$9.49M Sell
70,047
-17,653
-20% -$2.41M 0.46% 84
2023
Q2 		$12.6M Sell
87,700
-75,439
-46% -$11.1M 0.58% 82
2023
Q1 		$22.6M Buy
163,139
+92,003
+129% +$12.4M 0.59% 84
2022
Q4 		$9.65M Sell
71,136
-12,393
-15% -$1.55M 0.55% 83
2022
Q3 		$9.16M Sell
83,529
-18,978
-19% -$2.41M 0.56% 84
2022
Q2 		$13.5M Buy
+102,507
New +$13.5M 0.77% 61
2017
Q1 		– Sell
-4,550
Closed -$249K – 142
2016
Q4 		$249K Sell
4,550
-2,000
-31% -$114K 0.02% 150
2016
Q3 		$430K Hold
6,550
– – 0.03% 129
2016
Q2 		$395K Hold
6,550
– – 0.03% 132
2016
Q1 		$369K Hold
6,550
– – 0.02% 136
2015
Q4 		$445K Hold
6,550
– – 0.03% 122
2015
Q3 		$417K Sell
6,550
-11,450
-64% -$753K 0.03% 122
2015
Q2 		$573K Buy
18,000
+10,400
+137% +$712K 0.02% 226
2015
Q1 		$520K Buy
7,600
+2,900
+62% +$201K 0.03% 115
2014
Q4 		$331K Hold
4,700
– – 0.02% 135
2014
Q3 		$336K Sell
4,700
-300
-6% -$22K 0.02% 133
2014
Q2 		$372K Sell
5,000
-1,000
-17% -$72.3K 0.02% 125
2014
Q1 		$389K Hold
6,000
– – 0.02% 121
2013
Q4 		$356K Hold
6,000
– – 0.02% 121
2013
Q3 		$312K Hold
6,000
– – 0.02% 123
2013
Q2 		$284K Buy
+6,000
New +$306K 0.02% 134

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Braun Stacey Associates's AZN Position: Q3 2024 in Review

Braun Stacey Associates sold out of AstraZeneca (AZN) in Q3 2024, closing a stake of 10,163 shares — an estimated $1.59M sold.

Braun Stacey Associates first reported a position in AZN in Q2 2013 and held it in 24 quarters. The position peaked at $22.6M in Q1 2023. 1,230 funds tracked by Wall St. Rank hold AZN as of Q3 2024.

  • Braun Stacey Associates reported no remaining AstraZeneca position as of Q3 2024 after selling out during the quarter.
  • Braun Stacey Associates sold 10,163 AstraZeneca shares in Q3 2024, an estimated $1.59M.
  • Braun Stacey Associates first reported a position in AstraZeneca in Q2 2013 and held it in 24 quarters.
  • Braun Stacey Associates's AstraZeneca position peaked at $22.6M in Q1 2023.
  • 1,230 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.

Based on Braun Stacey Associates's 13F filing for Q3 2024, filed 7 Nov 2024.